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Abstract:  Immune responses against HSV-1 and HSV-2 are complex and involve a 
delicate interplay between innate signaling pathways and adaptive immune responses. The 
innate response to HSV involves the induction of type I IFN, whose role in protection 
against disease is well characterized in vitro and in vivo. Cell types such as NK cells and 
pDCs contribute to innate anti-HSV responses in vivo. Finally, the adaptive response 
includes both humoral and cellular components that play important roles in antiviral 
control and latency. This review summarizes the innate and adaptive effectors that 
contribute to susceptibility, immune control and pathogenesis of HSV, and highlights the 
delicate interplay between these two important arms of immunity. 
Keywords: Herpes Simplex virus (HSV); innate immunity; antiviral signaling; type I 
interferon (IFN); Natural killer (NK) cells; plasmacytoid dendritic cells (pDCs); adaptive 
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1. Introduction 
Herpes simplex virus (HSV) is a highly successful human pathogen belonging to the family 
Herpesviridae. Two serotypes of the alpha herpesviruses, HSV-1 and HSV-2, are the causative agents 
of oral and genital herpes, whose lifelong infections are highly prevalent in North America and 
worldwide. The immune response to these pathogens is complex and multifactorial; likewise, these 
ancient viruses have multiple viral evasion mechanisms that have secured their evolutionary success. 
Therefore, the study of anti-HSV immune responses as well as the corresponding viral 
countermeasures is important to our understanding of antiviral immunity and viral pathogenesis in 
general.  
The immune response against HSV involves both innate and adaptive immune mechanisms. The 
innate antiviral response is thought to play a pivotal role in determining the outcome of an HSV 
infection. Accordingly, the production of type I interferon (IFN), comprised largely of IFNα and IFNβ, 
has been linked to protection against disease in both mouse models and in human studies  [1-9]. In 
addition, multiple cell types have been shown to contribute to the innate immune responses to HSV in 
vivo. Among the most important of these cell types are natural killer (NK) cells, whose role in anti-
HSV immunity involves cytokine production, recognition, and killing of virally infected cells, and 
plasmacytoid dendritic cells (pDCs), whose primary role involves type I IFN production in vivo   
[10-14]. 
In addition, the adaptive immune response has been shown to play important roles in disease 
progression, latency and control of virus spread. Neutralizing antibody levels have been negatively 
correlated with disease severity  [15-17]; however, conflicting studies have failed to identify a precise 
role for the antibody-mediated response to HSV in vivo in murine models of infection  [16,18]. The 
cellular response is highly involved in antiviral defense, with CD8+ T cells playing an important role 
in this process, largely through the production of IFN  [19-22]. A minor role for CD4+ T cells has 
been described, with these cells providing some degree of protection in the absence of other immune 
effectors  [20-23]. 
In this review, we summarize the current findings that characterize the role of both innate and 
adaptive immune responses against HSV. We first discuss the innate antiviral signaling pathways that 
lead to type I IFN production, as well as the corresponding downstream effector pathways. Second, we 
describe the role of NK cells and pDCs in the establishment of innate immunity in vivo. Finally, we 
discuss the role of both humoral and cell-mediated immunity as it contributes to protection, viral 
control and reactivation. 
 
2. The role of type I interferons in vivo 
 
The type I IFNs are key factors involved in the host defense against HSV. Interest in the 
involvement of these cytokines in the resistance to HSV began with the observation that different 
strains of mice show significant variation in their susceptibility to infection with HSV-1, with 
C57BL/6 mice demonstrating a much higher resistance compared to the A and BALB/c strains of 
mice  [3]. Many groups have suggested that this observation could be attributed to differences between 
mouse strains in their ability to mount a rapid type I IFN response  [2,4,9,24], although alternative Viruses 2009, 1                              
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explanations were proposed   [25-31]. Recent studies, however, have more clearly confirmed the 
importance of type I IFN in HSV resistance. For example, based on experiments using SCID mice, 
which lack lymphocytes but have normal innate immune responses  [32], Halford et al. have suggested 
that the difference between mouse strains historically categorized as “resistant” (C57BL/6) or 
“susceptible” (BALB/c mice) can be explained by the increased ability of C57BL/6 to develop a rapid 
type I IFN response  [33]. Studies using IFNα/β receptor knockout mice have further substantiated this 
observation, as increased viral replication and pathogenesis as well as decreased survival have been 
shown in these mice after genital infection with HSV-2  [34-36] and ocular or footpad challenge with 
HSV-1  [37,38]. Finally, Vollstedt et al. have demonstrated that mice lacking type I IFN signaling 
have strongly increased susceptibility to intraperitoneal inoculation with HSV-1, while mice deficient 
in the recombination activating gene (RAG), which have intact IFN responses but no mature T or B 
cells, showed resistance to HSV-1 infection  [6]. The influential function of the type I IFNs in the 
defense against HSV has been corroborated by reports that human patients suffering from unusually 
severe infections with HSV, such as herpes simplex encephalitis, often have defects in type I IFN 
signaling  [39-41]. These studies highlight the significant role of innate immunity, particularly of the 
type I IFN response, in resistance to HSV infection. 
 
3. Recognition of HSV and activation of type I IFN pathways 
 
The molecular mechanisms leading to the induction of antiviral immunity against viruses are multi-
faceted, and involve multiple cellular recognition events. The detection of viral components involves 
multiple pattern recognition receptors (PRRs) and results in signal transduction pathways that 
ultimately lead to the production of type I IFN. 
The type I IFN signaling pathway begins with the recognition of viral protein or nucleic acid. 
Recognition of viral ligands by PRRs leads to downstream signaling that ultimately converges on the 
activation of either Tank binding kinase 1 (TBK-1) or Inhibitor of NFB epsilon (IKK). The 
activation of these kinases leads to activation of IFN regulatory factor 3 (IRF-3), a transcription factor 
whose role in the expression of type I IFN and downstream pathways is thought to be of paramount 
importance. Activation of IRF-3, along with other transcription factors including NFB and ATF/cJun, 
leads to the production and secretion of type I IFN. Autocrine and paracrine signaling via type I IFN 
occurs through a JAK/STAT pathway and leads to the production of effector molecules known as IFN 
stimulated genes (ISGs), whose collective role is to limit viral replication and spread through the 
establishment of an antiviral state. 
 
3.1. Cellular sensors of HSV 
 
A wide variety of viral products serve as triggers for the cellular recognition of HSV infection, 
including nucleic acids and lipoproteins. The nucleic acid sensors can be categorized based on both 
localization and nucleic acid structure, and include the scavenger receptors, the retinoic acid inducible 
gene I (RIG-I)-like receptors (RLRs), the Toll-like receptors (TLRs), the Nod-like receptors (NLRs) 
and DNA-dependent activator of IRFs (DAI)  [42-47]. The viral protein sensors include the TLRs, 
which have been shown to recognize viral lipopeptides  [48,49].  Viruses 2009, 1                              
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The major trigger for cellular recognition of a viral infection appears to be viral nucleic acid, which 
can be recognized at multiple cellular locations. Extracellular dsRNA is detected at the cell surface by 
the class A scavenger receptors  [46,48]. Recent data suggest that these membrane-bound receptors 
recognize extracellular dsRNA and serve as chaperones to bring viral dsRNA into the cell for cytosolic 
recognition. In the endosomal compartment, TLR3 serves as a receptor for viral dsRNA and TLR9 
recognizes CpG-rich DNA   [14,42,50]. In the cytoplasmic compartment, RIG-I and melanoma 
differentiation associated gene 5 (MDA5) recognize viral dsRNA, with both redundancy and 
specificity with respect to both nucleic acid length and structure   [51,52]. The cytoplasmic DNA 
sensors include DAI as well as the inflammasome activators Nalp3 and absent in melanoma 2 
(AIM2)  [43,44,47,53]. A recent paper by Chiu et al. highlights the redundancy and overlapping nature 
of these sensors, as viral DNA processing by RNA polymerase III yields ssRNA with 5’ triphosphate, 
which serves as a ligand for RIG-I  [54].  
For HSV in particular, a number of these receptors have been implicated specifically in the 
recognition of viral nucleic acids or proteins. For example, Wang et al. have suggested a direct role for 
DAI in sensing HSV infection, due to the ability of the DAI inhibitor adenosine deaminase acting on 
RNA 1 (ADAR1) to suppress HSV-1-mediated IFNβ gene expression   [55]. In addition, HSV-1 
infection activates the inflammasome, presumably through the nucleic acid sensor Nalp3  [47]. RIG-I 
has been recently implicated in the recognition of HSV in coordination with TLR9  [56,57].  
TLRs have been shown to recognize both nucleic acid and protein derived from 
HSV  [14,48,49,58,59]. In mice, four TLRs have been found to play a role in the resistance to HSV-1: 
TLR3, TLR9, and the TLR2/6 heterodimer, which recognize dsRNA, CpG-rich DNA and lipopeptides, 
respectively  [48,49,56,59,60]. HSV-1 infection via intranasal delivery causes 100% mortality in mice 
deficient in the TLR adaptor protein MyD88, suggesting that innate control via TLRs is important in 
limiting HSV-1 infection  [61]. Indeed, it has been shown in vivo that HSV-1-mediated production of 
IFN requires TLR9 and MyD88  [59,62].  
The importance and downstream sequelae of TLR recognition of HSV is complex and context-
dependent. TLR9 appears to play only a minor role in the defense against HSV despite its requirement 
for IFN production by pDCs. In the absence of TLR9, there was no change in either viral load in the 
nervous system or overall survival following infection with HSV-1  [59,62]. Furthermore, Kurt-Jones 
et al. have demonstrated that TLR2 mediates the production of inflammatory cytokines in response to 
HSV-1 infection, leading to the development of lethal viral encephalitis  [49]. Taken together, this 
evidence suggests that while the precise role of TLRs in the innate response to HSV in vivo are not 
fully understood, they appear to have a role in mediating both immune protection as well as immune 
pathology. Not surprisingly, there has been a great deal of recent interest in using TLR ligands to treat 
or prevent HSV infection. A number of groups have revealed that mucosal delivery of ligands for 
TLR3 and TLR9, but not TLR2 or TLR4, are protective against genital infection with HSV-2   
  [35,63-68]. Similarly, intranasal application of a ligand for TLR3, but not for TLR4 or TLR9, 
protected against HSV encephalitis in mice  [69]. The therapeutic approach of using TLR ligands to 
treat HSV is an area that requires further investigation, since the downstream consequences of TLR 
engagement in vivo remain to be clarified. 
While viral nucleic acid and protein serve as potent triggers of antiviral signaling, increasing 
evidence suggests a role for the viral entry event in innate immune responses to virus. IRF-3 activation Viruses 2009, 1                              
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and ISG induction occur in response to virus particle entry in the absence of replication  [70-76]. Data 
from our laboratory has demonstrated that the cellular response to virus particle entry requires IRF-3 
and induces ISGs in the absence of IFN production and viral replication in primary fibroblasts  [71]. In 
this pathway, NFB is not activated and IRF-3 is a crucial component, as siRNA-mediated knockdown 
of IRF-3 abrogates this response  [73,74]. This immediate early response does not depend on RIG-I, or 
any of the known TLRs  [74]. Given the multifaceted nature of viral entry, cellular changes associated 
with this fusion event may serve as a danger signal for induction of an antiviral response. Indeed, 
generic stress signals such as ATP hydrolysis and changes to intracellular potassium ion concentration 
are sufficient triggers to induce an antiviral response by activating the Nalp3 inflammasome  [77-79], 
suggesting that antiviral signaling may occur by virus recognition through danger associated patterns 
rather than by classical pathogen associated molecular patterns (PAMPs). The specific cellular stress 
and the corresponding danger recognition receptor involved in virus entry remain unknown, but have 
important implications in innate antiviral signaling.  
 
3.2. Signal transduction pathways leading to type I IFN production 
 
Following virus recognition by various cellular receptors, signal transduction events lead to the 
expression of type I IFNs. The cytosolic RIG-I, MDA5 and DAI pathways converge at the 
mitochondrial surface. Here, the adaptor protein MAVS associates with the nucleic acid sensor and 
recruits components of the antiviral signaling complex including TBK-1/IKK, the adaptor protein 
mediator of IRF-3 activation (MITA, also known as STING), and IRF-3  [58,80-82]. The cellular 
components involved downstream of scavenger receptor binding and following recognition of virus 
entry are less well characterized, but like the other known sensors, the pathway appears to converge at 
the activation of the kinases TBK-1/IKKe  [71,74,80,81]. TLR3-mediated recognition of virus also 
leads to activation of TBK-1 and IRF-3 in a TRIF-dependent manner, independent of MAVS or 
MITA  [42]. Dimerization and activation of TBK-1 at the mitochondrial surface leads to activation of 
IRF-3  [80,81,83], resulting in IFNβ transcription  [84-89]. Not surprisingly, the HSV-1 immediate 
early gene product ICP0 has been shown to block IRF-3 activity and prevent IFN transcription, 
highlighting the importance of IRF-3 in the antiviral cascade  [90-92]. 
Type I IFN is thought to act autocrinely and paracrinely to generate a positive feedback loop that 
results in the induction of over 2000 ISGs. IFNβ signaling occurs through a JAK/STAT mechanism 
that leads to the induction of IFNα subspecies as well as ISGs such as IRF-7. IRF-7 is thought to be a 
master regulator of type I IFN production, as its activation is important to induce the full range of ISGs 
involved in eliciting an antiviral state during the late or amplification phase of the antiviral response, 
particularly in plasmacytoid dendritic cells (pDCs)  [93]. 
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3.3. Downstream effector pathways 
 
The antiviral state is established by the collective activity of ISGs. These effectors have multiple 
distinct and overlapping functions, including inhibition of viral protein expression, apoptosis, and 
recruitment of immune cells to sites of infection  [94-98]. These effector proteins are particularly 
important in the establishment of antiviral immunity against HSV, and their role is highlighted by the 
multiple viral countermeasures employed by HSV against these genes (reviewed in   [99]). 
Promyelocytic leukemia (PML) protein forms ND10 nuclear structures   [100], which have been 
implicated in a number of cellular antiviral processes, including the induction of apoptosis and major 
histocompatibility complex (MHC) class I antigen presentation  [101,102]. Its importance in the innate 
response against HSV is highlighted by the fact that ICP0 disrupts these nuclear bodies, and 
knockdown of PML by shRNA increases viral gene expression and replication in primary 
fibroblasts   [103,104]. Protein kinase R (PKR) is an IFN-inducible dsRNA-binding protein that 
phosphorylates and inhibits the activity of the eukaryotic translation initiation factor eIF2, thus 
preventing viral gene expression   [105]. Accordingly, mice deficient in PKR have increased 
susceptibility to HSV-1 and HSV-2  [106]. In fact, it has been suggested that the PKR pathway is key 
to the ability of IFNα1 to mediated defense against HSV-2   [107]. Two HSV-1 encoded genes, 
ICP34.5 and Us11, counteract PKR activity by dephosphorylating eIF2 and by competing for dsRNA 
binding, respectively  [108,109]. Finally, the HSV-encoded viral host shutoff (vhs) protein inhibits 
host gene expression and decreases type I IFN production  [110], attesting to the importance of this 
signaling pathway. 
 
4. Cell type specific contributions to innate immunity against HSV 
 
In vivo, several cell types contribute to the innate immune response against HSV. NK cells play an 
important role in both cytokine production and in recognition and killing of virally infected cells. In 
addition, the role of pDCs in the anti-HSV response has been described. Indeed, these cells were 
originally identified as natural IFN producing cells, as they are the major producers of IFN in vivo.  
 
4.1. NK cells 
 
NK cells are important cellular components of the innate immune response. They have two major 
roles: to kill tumor or infected cells and to produce cytokines such as IFNγ  [10,12,13]. The binding of 
ligands to either NK inhibitory or activating receptors determines the effector function of these 
cells   [111,112]. Inhibitory receptors recognize MHC class I proteins on the uninfected cells and 
prevent NK cell activation  [11]. Virus-mediated downregulation of MHC is a common mechanism of 
viral immune escape, as it prevents antigen presentation and adaptive antiviral responses. However, 
downregulation of MHC causes a decrease in inhibitory signals to the NK cell, leading to its activation 
and the lysis of the target cell (reviewed in  [113]). Indeed, the HSV immediate-early protein ICP47 
downregulates MHC class I by binding the cellular antigen transporter TAP1, preventing the transport 
of MHC molecules to the cell surface  [114]. While this allows the virus to evade detection by CD8+ T 
cells, the absence of MHC increases the susceptibility of infected cells to NK lysis   [115-117]. Viruses 2009, 1                              
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Importantly, NK cells also contain activation receptors which may directly detect viral proteins, 
leading to viral clearance  [118].  
Attempts to define a role for NK cells against HSV using depletion studies have yielded conflicting 
results. A number of studies have suggested that NK cell depletion via anti-NK1.1 or anti-asialo-GM1 
antibodies increases the susceptibility of mice to ocular, genital, cutaneous and intravascular challenge 
with HSV  [119-125]. In contrast, others have found that the depletion of NK cells with anti-asialo-
GM1 antibodies does not impair the defense against intraperitoneal or footpad challenge with 
HSV  [126-128]. In all cases, however, the findings of these studies are limited by the fact that asialo-
GM1 expression is found on cell types other than NK cells, including epidermal dendritic cells, 
macrophages and activated T cells  [129-132], while the NK1.1 antigen is not expressed on all NK 
cells, and can also be found on virus-specific activated T cells  [133,134]. These discrepancies were 
underscored in an elegant study by Halford et al, who found that treatment with anti-asialo GM1 
antibodies increased HSV-1 titers after ocular inoculation in BALB/c mice but not in SCID 
mice   [133]. This observation implies that the anti-asialo-GM1 treatment exerted its effects on a 
lymphocyte population not present in SCID mice as opposed to NK cells, which are present in both 
strains.  
In support of the involvement of NK cells in the defense against HSV, adoptive transfer of NK 1.1
+ 
and asialo GM-1
+ cells restores resistance to HSV, while transfer of cells from beige mice, which are 
deficient in NK cells, does not   [135]. In another study, mice lacking both NK cells and T cells 
developed severe CNS infection leading to mortality after intranasal infection with HSV-1, while mice 
deficient only in T cells did not  [136]. It has also been established that mice deficient in CCR5 
expression suffer from increased susceptibility to genital challenge with HSV-2  [125]. These mice 
display no differences in T cell or total leukocyte recruitment, but decreased NK cell recruitment and 
activity was observed. In addition, Ashkar et al. compared the susceptibility to intravaginal challenge 
with HSV-2 in a number of mouse strains and found that the two most susceptible strains lack NK and 
NKT cells  [63]. IL-15
-/- mice, which lack NK and NKT cells  [137], showed higher susceptibility than 
mice lacking both T and B cells  [63]. However, these findings are somewhat confounded by the fact 
that IL-15 is capable of producing antiviral effects in the absence of NK and NKT cells  [138]. Finally, 
Grubor-Bauk et al. used mice deficient in CD1, which is required for the development of NKT cells, to 
show that this cell subset is important for the control of viral spread and morbidity in the HSV-1 
zosteriform model  [139]. 
In contrast, several studies have suggested that NK cells are not essential to the defense against 
HSV. For instance, despite a correlation between virulence of HSV strains and their ability to activate 
NK cells, treatments that strongly increased NK cell activity were unable to protect mice from HSV 
pathology and mortality  [140]. In another study, Vollstedt et al. compared rag2
-/
- mice (which are 
deficient in T and B cells) and rag2
-/
- γc
-/
- mice (which have an additional deficiency in NK cells) and 
found that NK cells are not required for resistance to HSV-1  [6]. Finally, mice overexpressing IL-15 
were unable to survive HSV challenge, despite having higher numbers of NK cells and lower viral 
titers early in the infection  [141].  
The variation in the role of NK cells in the defense against HSV may be due, in part, to differences 
between the strains of mice and viruses used, as well as the mechanism of NK cell depletion and the 
route of inoculation. It is also difficult to assess whether studies in mice are applicable to humans. For Viruses 2009, 1                              
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example, although ICP47 binds human TAP1 with very high affinity, it interacts much less efficiently 
with murine TAP1, and thus, MHC class I transport is not as efficiently interrupted in mice  [142]. 
Therefore, the murine model of HSV infection may not be as susceptible to NK cell-mediated lysis as 
would be expected in a human patient. Indeed, there is evidence to suggest that NK cells are important 
in the innate response against HSV in humans. For instance, patients with severe infections with HSV, 
including newborns and those with Wiscott-Aldrich syndrome, have low NK cell activity  [143]. In 
addition, the only detectable defect in the immune response of a patient suffering from recurrent severe 
herpes virus infections was a lack of NK cell activity  [144]. More recently, Dalloul et al. showed that 
for two patients with unusually severe HSV infections, pDCs and NK cells could not be detected in the 
blood and NK cells could not be generated in culture  [145]. They suggested that this phenotype is due 
to the absence of NK cell function, since type I IFN was detected in the serum. Therefore, a role for 
NK cells in the defense against HSV in humans exists; however, their contribution to innate anti-HSV 
immunity may be underappreciated in mouse models of infection. 
 
4.2. pDCs 
 
pDCs are a functionally distinct subset of DCs whose predominant effector function is the 
production of type I IFNs. pDCs constitutively express IRF-7, which is involved in the amplification 
phase of IFN production, and are known to make large amounts of IFNα in response to infection with 
HSV-1, both in mouse models and in humans  [93,146,147]. These cells are also thought to be poor 
presenters of antigen and are considered professional IFN producing cells (pIPCs). 
Given the importance of type I IFN in the innate response to HSV, one would predict that pDCs 
would be implicated in the defense against this virus. However, the function of these cells in the 
context of an HSV infection has not been well studied. pDCs were first described in 1999 by Siegal  
et al. as natural interferon producing cells in response to HSV exposure  [147]. It was subsequently 
reported in a mouse model of genital infection that pDCs can recognize HSV-2 exclusively via 
TLR9  [14]. In fact, mice deficient in either pDCs or TLR9 show similar survival curves when infected 
with HSV-2  [60]. However, others have shown that in TLR9-deficient mice, pDCs from some tissue 
sources are capable of limited production of IFNα in response to HSV-1, and thus a minor alternative 
pathway for HSV detection must exist  [148]. In support of a role for pDCs in the defense against 
HSV, severe inflammation and tissue destruction was seen in pDC deficient mice after genital 
infection with HSV-2, although mice deficient in TLR9 showed more profound tissue damage  [60]. 
With respect to humans, patients with atopic dermatitis have been found to have decreased numbers of 
pDCs in the epidermis, which might account for their increased susceptibility to HSV   [149]. In 
addition, an association between low pDC counts and severe recurrent infections with HSV in human 
patients has been recently proposed  [150]. Although pDCs do not support a productive infection by 
HSV-2, they infiltrate into recurrent HSV genital lesions in human patients; however, their ability to 
act as APCs remains controversial  [151]. Taken together, these data suggest that pDCs may play 
significant roles in the innate and adaptive response to HSV infection, although further study is 
required to clarify the function of these cells in antiviral defense. 
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5. Adaptive immune mechanisms against HSV 
 
While innate immunity is thought to play a paramount role in the resistance to HSV, the adaptive 
immune mechanisms mediating antigen-specific responses cannot be overlooked. Neutralizing 
antibodies are produced against HSV following infection in both mice and humans, despite playing a 
seemingly minor role in pathogenesis and immune protection. While earlier studies have elucidated a 
role for antibody-mediated protection against infection, a growing body of literature highlights the 
crucial role of cellular immunity, particularly CD8+ T cell-mediated immunity, against HSV. 
Specifically, the IFNγ-mediated effector functions of CD8+ T cells have been well described and 
contribute to survival against challenge, maintenance of latency, and limiting of viral spread. In 
addition, a role for the type I IFNs in CD8+ T cell-mediated immunity highlights the close interaction 
between the innate and adaptive arms of the immune response against HSV. 
 
5.1. Humoral immunity against HSV 
 
While infection with HSV results in the production of neutralizing antibodies, the role of the 
humoral response in the control of pathogenesis and spread is controversial. On one hand, antibody 
levels do not determine the outcome of HSV infection in humans. Infants with passive immunity are 
still capable of being infected and neutralizing antibodies fail to provide sterilizing immunity against 
infection   [152-154]. Passive transfer of immune serum from immunized mice has shown no 
appreciable effect on viral replication in either the genital tract or the nervous system, implying a 
nonessential role in both the local control of infection as well as the establishment of latency in the 
nervous system  [16]. 
On the other hand, early studies in mouse models of HSV-2 have identified a functional role for 
antibody-mediated protection against transmission. Studies by Zeilin et al. and Sherwood et al. have 
shown that administration of anti-HSV antibodies leads to protection against HSV-2 transmission in a 
vaginal model of infection   [155,156]. In these studies, antibody-treated mice have a reduced 
frequency of clinical disease and/or reduced viral titers at the site of infection. These studies are 
supported by more recent evidence demonstrating that intraperitoneal administration of a gD-specific 
antibody reduced the viral load in the vaginal epithelium and protected against the onset of 
disease  [157]. Despite these findings in mice, a lack of clinical verification in humans highlights the 
need for a better understanding of humoral contributions to HSV control. 
The humoral response against HSV has also been associated with long-term effects. Milligan et al. 
demonstrated a sustained detection of HSV-2-specific plasma cells in the bone marrow and spinal 
cords of infected mice and guinea pigs following vaginal inoculation  [158]. Whether antibody levels 
are strongly correlated with disease severity or reactivation from latency has not been well established. 
However, evidence from patients with recurring HSV-2 infections demonstrates that IgG1 and IgG3 
levels correlate with recurrence of outbreaks   [17]. Accordingly, HSV encoded countermeasures 
against FcR provide support for antibody-mediated protection  [159,160].  
Studies in B cell deficient mice also support a role for humoral immunity in immune protection. 
While MT B cell deficient mice were able to control replication in the genital mucosa, they were not 
completely protected against disease  [16]. In cyclophosphamide-induced immunosuppressed mice, Viruses 2009, 1                              
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passive transfer of HSV-1 antiserum led to protection in 100% of mice from mortality, whereas none 
of the mice receiving control serum survived the challenge, providing strong evidence for a role for 
antibody-mediated protection against disease progression in the absence of other immune 
effectors  [161]. In an ocular model of HSV-1 infection, it was observed that B cell deficient mice are 
more susceptible to herpetic encephalitis and keratitis, have increased viral persistence in the eye and 
increased dissemination to the corneal stroma  [162]. As these mice are deficient in T cell mediated 
immune responses, they generate minimal Th2 responses such as IL4 and IL10 and have diminished 
proliferative capacity in response to HSV antigen stimulation. Therefore, the role of humoral immunity 
extends to a role in regulating T cell mediated responses to HSV that correlate with disease severity. 
Consistent with this observation, Dudley et al. found that the antibody contribution to HSV-2 vaginal 
shedding disappeared following T cell depletion, suggesting that humoral immunity requires a cellular 
component  [163].  
Taken together, the specific contribution of humoral immunity to HSV control is not clear. While 
antibodies against HSV can mediate prophylatic protection in mice, B cells are not absolutely required 
for protection in the context of an acute infection, and likely interact with other immune effectors such 
as T cells. As such, a better understanding of this area of HSV immunity is warranted. 
 
5.2. Cellular immunity against HSV 
 
It has been shown that CD8+ T cells are recruited to HSV-2 lesions and that infiltration of this cell 
type occurs early in infection, contributing heavily to immune control and cytolysis. In a cutaneous 
murine model of HSV-1 infection, proliferation of gB-specific CD8+ T cells occurred less than 48 
hours post infection and correlated with cytolytic activity  [164]. gB is an immunodominant epitope 
against which CD8+ T cells are produced; however, gB-nonspecific CD8+ T cells have been identified 
that have a similar phenotype to gB-specific CD8+ T cells with respect to surface markers, cytokine 
production, and lysis  [165]. This observation suggests that subdominant epitopes contribute equally to 
the CD8+ T cell response. Not surprisingly, the CD8+ T cell response in patients with genital herpes 
has been shown to be broadly reactive, with no evidence that responses against specific viral epitopes 
correlate with outcome  [166]. 
The antiviral effects of CD8+ T cells have been well described, with IFN playing a crucial role in 
this process. For example, neutralizing antibodies against IFN lead to impaired resolution of HSV-2 
infection  [19-22]. In a model of genital HSV-2 infection, IFNγ produced by T cells and not NK cells 
was required for survival against challenge, although this cytokine is made by both cell types  [21]. 
The cellular response against a TK-negative strain of HSV-2 led to viral control in an intravaginal 
model of infection in an IFN-dependent manner   [19]. Not surprisingly, IFNR
-/- mice show 
significant mortality in response to HSV-1  [167], suggesting a crucial role for this signaling pathway 
in disease progression. 
Given the crucial role of this cell type in the defense against HSV, early establishment of CD8+ T 
cell responses has been explored as a means of preventing establishment of latency; however, this 
therapeutic strategy has proved less promising in animal models, which establish a latent infection 
despite lower viral copy numbers in neural sites as well as decreased viral titers at the site of 
infection  [168]. In fact, multiple studies provide evidence that IFN-producing CD8+ T cells persist Viruses 2009, 1                              
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during neuronal latency in areas of T cell infiltration   [165,169], suggesting persistent antigen 
stimulation and T cell activation during latency despite a failure to clear the infection. Consistent with 
this finding, Posavad et al. found that patients with frequently recurring HSV-2 outbreaks displayed 
long-term persistence of CD8+ T cells with CTL activity and no evidence of T cell exhaustion  [170]. 
HSV-specific CD8+ T cells have been shown to play a role during HSV latency. In an ex vivo 
reactivation model, CD8+ T cells reduce viral spread from latently infected trigeminal ganglion cells 
to surrounding fibroblasts in a co-culture system   [165]. This evidence is supported by Cantin et 
al.  [171], who observed no significant differences between wild-type, IFN
-/-, and IFNR
-/- mice with 
respect to establishment of latency following HSV-1 infection in vivo. Rather, these knockout mice 
exhibit greater viral gene expression in neurons following reactivation compared to wild-type mice, 
suggesting that IFN contributes to viral control following reactivation from latency as opposed to 
during the latent phase itself.  
In addition to a critical role for CD8+ T cell-mediated antiviral activity against HSV, there is 
evidence supporting a role for CD4+ T cells in controlling infection. T cell depletion studies have 
shown that both CD4+ and CD8+ T cells contribute to protection against HSV-2 replication in the 
local mucosa  [172]. While CD8+ effectors are generally thought to be the dominant adaptive immune 
cell type contributing to protection, it has been recently shown that in both CD8-depleted and   
CD8-deficient mice, CD4+ T cells are sufficient to clear virus from both the local mucosal as well as 
neural sites, implying a compensatory role for CD4+ T cells in the absence of CD8+ T cell-mediated 
protection   [23]. This CD4+ T cell-mediated clearance does not rely on Fas or perforin activity, 
suggesting a non-lytic mechanism for CD4+ T cell effector function. Rather, CD4+ T cells from these 
mice secrete high levels of IFN, highlighting the critical role of this cytokine against HSV. Likewise, 
Iijima et al. describe an IFN--mediated role for CD4+ T cells in clearance of HSV-2 from the vaginal 
mucosa following secondary challenge  [20]. 
A number of studies have suggested that a synergistic interaction exists between the type I IFNs and 
IFNγ  [6,38,173-180]. It has been shown that mice lacking receptors for both type I and type II IFNs 
experience a dramatic increase in susceptibility to HSV-1  [6,38], while the absence of either receptor 
alone causes a much lesser increase in susceptibility  [38]. As well, treatment with IFNβ plus IFNγ has 
been shown to generate a strong decrease in viral replication as well as protection from HSV-1 
pathogenesis in a mouse ocular model  [178]. Finally, mice lacking STAT1, a key factor in type I and 
II IFN signaling, are profoundly susceptible to infection with HSV-1  [133,181].  
A few distinct mechanisms for this synergy have been described. For example, IFN has been 
shown to directly act on CD8+ T cells to mediate cross-presentation of antigen, leading to an 
expansion of antigen specific CD8+ T cells and specific lysis  [182,183]. In addition, a recent study by 
Trilling et al. demonstrated that IFNγ acts in part through IRF-1 to control Vaccinia virus replication 
in mouse cells in vitro   [184]. Interestingly, the involvement of IFNAR1, but not IFN, in   
IFNγ-mediation antiviral activity, suggests a complex synergy between these innate and adaptive 
cytokines. 
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6. Conclusion 
 
In conclusion, the immune response to HSV involves multiple mechanisms to recognize viral 
components and to target and lyse virally infected cells. The innate immune response represents a first 
line of defense against incoming virus and plays a crucial role in the early control of infection and 
spread. The molecular mechanisms underlying this response are numerous, overlapping and in some 
cases redundant, and largely lead to the production of antiviral protection via the type I IFNs. Both NK 
cells and pDCs play a leading role in innate control of infection. On the adaptive arm, antibody-
mediated protection plays a role, albeit controversial, in the response to HSV, with cellular   
IFNγ-dependent mechanisms playing a dominant role in control of spread. Finally, the complex 
interplay between innate and adaptive cytokines demonstrates the necessity of both arms of immunity 
against infection. 
However, multiple lines of conflicting evidence underscore a need for more accurate animal models 
of HSV that accurately represent the course of infection in vivo. In addition, the molecular mechanisms 
that govern viral recognition still need to be fully elucidated. Finally, manipulating these immune 
mechanisms into a strategic therapeutic or preventative vaccine against HSV is ongoing and requires 
further study. 
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